Tumor Biology

, Volume 37, Issue 7, pp 8869–8877 | Cite as

The tumor suppressive role of RASSF1A in osteosarcoma through the Wnt signaling pathway

  • Wei-Guo Wang
  • Shi-Jie Chen
  • Jin-Shen He
  • Jing-Song Li
  • Xiao-Fang Zang
Original Article


Ras-association domain family 1 isoform A (RASSF1A) is a tumor suppressor gene and its expression is lost in numerous types of cancer cells, including primary osteosarcoma cells. However, its functional significance in osteosarcoma has not been well defined. The messenger RNA (mRNA) expression of RASSF1A in osteosarcoma tissues and corresponding non-tumoral tissues was measured by real-time PCR. Overexpression of RASSF1A was established by an adenoviral vector expressing RASSF1A. Cell migration and invasion were analyzed in transwells. Apoptosis and cell cycle were analyzed using flow cytometry. Wnt/β-catenin activity was measured by TCF reporter dual-luciferase assay. Cell viability was measured by MTT assay. Protein expression was detected by Western blot. RASSF1A mRNA expression was significantly lower in osteosarcoma tissues than that in the corresponding non-tumoral tissues. The lowered RASSF1A expression correlated with the clinical severity of osteosarcoma. rAd-RASSF1A injection significantly inhibited the growth of xenograft MNNG/HOS tumors in mice. Overexpression of RASSF1A resulted in significant inhibition of the proliferation, migration, and invasion; induced apoptosis; and arrested cell cycle at G0/G1 phase in both the MNNG/HOS and SaOS2 cells. Overexpression of RASSF1A inhibited the Wnt/β-catenin activity, decreased phosphorylation of Akt/glycogen synthase kinase-3-β (GSK3-β), and increased phosphorylation of mammalian sterile 20-like kinase 1 (MST1). Overexpression of RASSF1A downregulated the cyclin D1, c-Myc, and matrix metalloproteinase-7 (MMP-7) protein levels. RASSF1A functions as a tumor suppressor in osteosarcoma and exerts anti-cancer roles through regulating Akt/GSK-3-Wnt/β-catenin signaling.


Osteosarcoma Wnt RASSF1A β-catenin 


Compliance with ethical standard

The study was pre-approved by the Institutional Ethics Committee of the Third Xiangya Hospital and written informed consent was obtained from all patients.

Conflicts of interest



  1. 1.
    Bruland OS, Hoifodt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res. 2005;11:4666–73.CrossRefPubMedGoogle Scholar
  2. 2.
    Himelstein BP. Osteosarcoma and other bone cancers. Curr Opin Oncol. 1998;10:326–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Bacci G, Longhi A, Cesari M, Versari M, Bertoni F. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients. Cancer. 2006;106:2701–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Picci P, Mercuri M, Ferrari S, et al. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol. 2010;21:1366–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Pfeifer GP, Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc). 2005;70:576–83.CrossRefGoogle Scholar
  6. 6.
    Dammann R, Schagdarsurengin U, Seidel C, et al. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 2005;20:645–63.PubMedGoogle Scholar
  7. 7.
    Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20:1509–18.CrossRefPubMedGoogle Scholar
  8. 8.
    Amin KS, Banerjee PP. The cellular functions of RASSF1A and its inactivation in prostate cancer. J Carcinog. 2012;11:3.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    9. Zhou PH, Zheng JB, Wei GB, et al. Lentivirus-mediated RASSF1A expression suppresses aggressive phenotypes of gastric cancer cells in vitro and in vivo. Gene Ther 2015.Google Scholar
  10. 10.
    Fu L, Zhang S. RASSF1A promotes apoptosis and suppresses the proliferation of ovarian cancer cells. Int J Mol Med. 2014;33:1153–60.PubMedGoogle Scholar
  11. 11.
    Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem. 2011;286:6253–61.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Oh HJ, Lee KK, Song SJ, et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 2006;66:2562–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Lim S, Yang MH, Park JH, et al. Inactivation of the RASSF1A in osteosarcoma. Oncol Rep. 2003;10:897–901.PubMedGoogle Scholar
  14. 14.
    Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002;21:4345–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Li C, Shi X, Zhou G, et al. The canonical Wnt-beta-catenin pathway in development and chemotherapy of osteosarcoma. Front Biosci (Landmark Ed). 2013;18:1384–91.CrossRefGoogle Scholar
  16. 16.
    MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hoang BH, Kubo T, Healey JH, et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res. 2004;64:2734–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Liu Y, Wang W, Xu J, et al. Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/beta-catenin signaling. Oncol Rep. 2013;30:1723–30.PubMedGoogle Scholar
  19. 19.
    Lin CH, Guo Y, Ghaffar S, et al. Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma. 2013;2013:147541.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Feng L, Li J, Yan LD, Tang J. RASSF1A suppresses proliferation of cervical cancer cells. Asian Pac J Cancer Prev. 2014;15:5917–20.CrossRefPubMedGoogle Scholar
  21. 21.
    Dallol A, Agathanggelou A, Tommasi S, et al. Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res. 2005;65:7653–9.PubMedGoogle Scholar
  22. 22.
    Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol. 2002;22:4309–18.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    van der Weyden L, Papaspyropoulos A, Poulogiannis G, et al. Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis. Cancer Res. 2012;72:3817–27.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Yi M, Yang J, Chen X, et al. RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression. J Cell Physiol. 2011;226:2360–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A. 2001;98:7504–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kuzmin I, Gillespie JW, Protopopov A, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 2002;62:3498–502.PubMedGoogle Scholar
  27. 27.
    Thaler S, Hahnel PS, Schad A, Dammann R, Schuler M. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res. 2009;69:1748–57.CrossRefPubMedGoogle Scholar
  28. 28.
    Cai Y, Cai T, Chen Y. Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J Cell Biochem. 2014;115:625–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.CrossRefPubMedGoogle Scholar
  30. 30.
    McCubrey JA, Steelman LS, Bertrand FE, et al. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia. 2014;28:15–33.CrossRefPubMedGoogle Scholar
  31. 31.
    Kitagishi Y, Nakanishi A, Ogura Y, Matsuda S. Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer’s disease. Alzheimers Res Ther. 2014;6:35.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Wei-Guo Wang
    • 1
  • Shi-Jie Chen
    • 1
  • Jin-Shen He
    • 1
  • Jing-Song Li
    • 1
  • Xiao-Fang Zang
    • 1
  1. 1.Department of Orthopaedic SurgeryThe Third Xiangya Hospital of Central South UniversityChangshaPeople’s Republic of China

Personalised recommendations